Findings

What do systematic reviews say?

232 questions · 234 findings · 11 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 68 · 29.1%GRADE not reported 0 · 0%Very low 57 · 24.4%Low 55 · 23.5%Moderate 48 · 20.5%High 6 · 2.6%

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 391 participants
Low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

FEV1 % predicted: absolute change from baseline · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1261 participants
Low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Quality of life perceived change in lifestyle after treatment · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Time off school or work · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Inhaled antibiotics vs IV antibiotics

Lung function · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Need for additional IV or oral antibiotics · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

It is very uncertain whether summary of findings: Inhaled antibiotics changes need for additional IV or oral antibiotics compared with IV antibiotics (very low certainty).

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 6.11 [0.33, 111.71]
1 study · 18 participants
Very low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Time to next pulmonary exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Microbiology Emergence of resistant organisms · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

Exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Participant‐reported symptom score Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Adverse events Â · adults and children with cystic fibrosis

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 27 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Sputum: volume · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Inhaled corticosteroids vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 250 participants
Low

Inhaled corticosteroids vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 250 participants
Low

Inhaled corticosteroids vs placebo

BHR: change in PC20 values · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 100 participants
Very low

Inhaled corticosteroids vs placebo

Change in exercise tolerance · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low